← 홈

프로그램 비교

타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-4 · 마지막 9월 2일

현재 선택: 1개 · 임상 갱신 필요 1개

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

프로그램 선택

API CSV14행 · 1개 프로그램
OverviewToxicologyClinical

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
AntibodyLimited DatastalePhase 2
Recombinant human adenovirus type 5＋Camrelizumab (Recombinant human adenovirus type 5＋Camrelizumab)
Zhejiang Cancer Hospital·Uterine Cervical Neoplasms
1 trials
Overview
Program
Recombinant human adenovirus type 5＋Camrelizumab
Overview
Company
Zhejiang Cancer Hospital
Overview
Modality
ANTIBODY
Overview
Target
Uterine Cervical Neoplasms
Overview
Indication
Uterine Cervical Neoplasms; Oncolytic Virotherapy
Overview
Phase
PHASE_2
Overview
Status
ACTIVE
Overview
Content status
Limited Data
Overview
Data Confidence
Data Confidence · Low
Overview
Development Signal
Development Signal · Emerging
Overview
Approval status
Investigational
Toxicology
Major finding
The safety and efficacy of recombinant human adenovirus 5 injection (H101) intraperitoneal administration combined with tislelizumab and platinum, fluorouracil-based drugs in the treatment of gastric cancer with peritoneal metastasis: an open-label, single-arm, prospective clinical study protocol.. This prospective, open-label, single-arm, exploratory clinical trial aims to evaluate the safety and…
Clinical
Safety signal
The safety and efficacy of recombinant human adenovirus 5 injection (H101) intraperitoneal administration combined with tislelizumab and platinum, fluorouracil-based drugs in the treatment of gastric cancer with peritoneal metastasis: an open-label, single-arm, prospective clinical study protocol.. This prospective, open-label, single-arm, exploratory clinical trial aims to evaluate the safety and…
Clinical
Program phase
PHASE_2